Open Interest and Volume Dynamics
The latest data reveals that Zydus Lifesciences’ open interest in futures and options contracts rose sharply by 4,314 contracts, an 18.43% increase from the previous figure of 23,403 to 27,717. This notable expansion in OI coincided with a substantial volume of 48,099 contracts traded, underscoring active participation in the derivatives market. The futures segment alone accounted for a value of approximately ₹88,798.53 lakhs, while the options segment’s notional value was an impressive ₹43,544.28 crores, culminating in a total derivatives value of ₹92,616.39 lakhs.
The surge in open interest alongside elevated volumes typically signals fresh capital inflows and new positions being established rather than mere unwinding of existing trades. This pattern often precedes significant price movements, as market participants position themselves for anticipated directional trends.
Price Performance and Technical Strength
Zydus Lifesciences’ underlying stock price closed at ₹1,196, just 0.48% shy of its 52-week high of ₹1,205. The stock has demonstrated consistent strength, outperforming its sector by 1.98% on the latest trading day and delivering a remarkable 9.12% return over the past eight consecutive trading sessions. This sustained upward momentum is further validated by the stock trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a robust bullish trend across multiple timeframes.
Investor participation has also intensified, with delivery volumes on 24 September reaching 11.02 lakh shares, a 41.56% increase compared to the five-day average delivery volume. This rise in delivery volume suggests genuine accumulation by investors rather than speculative intraday trading, reinforcing confidence in the stock’s near-term prospects.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Market Positioning and Directional Bets
The sharp rise in open interest combined with strong volume and price action suggests that market participants are increasingly bullish on Zydus Lifesciences. The stock’s mojo score of 71.0, upgraded from a previous Hold rating to a Buy on 22 September 2026, reflects improved fundamentals and technical outlook. This upgrade by MarketsMOJO highlights growing investor confidence and a positive shift in the company’s risk-reward profile.
Given the mid-cap status of Zydus Lifesciences with a market capitalisation of ₹1,19,461.06 crores, the stock offers a compelling blend of growth potential and liquidity. The current liquidity profile supports sizeable trade sizes, with the stock’s traded value comfortably accommodating transactions worth ₹3.89 crores based on 2% of the five-day average traded value.
Options market activity further corroborates this bullish stance. The substantial notional value in options contracts indicates that traders are actively deploying strategies that benefit from upward price movements, such as call buying or bull call spreads. The narrow trading range of just ₹1 on the latest session suggests consolidation, often a precursor to a breakout in the prevailing trend.
Sector and Benchmark Comparison
In contrast to the broader sector and benchmark indices, Zydus Lifesciences has outperformed notably. While the Pharmaceuticals & Biotechnology sector declined by 0.36% and the Sensex slipped 0.11% on the same day, Zydus Lifesciences gained 1.47%. This relative strength amid a subdued market environment underscores the stock’s resilience and attractiveness to investors seeking quality mid-cap exposure within the healthcare space.
Curious about Zydus Lifesciences Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Implications for Investors
For investors and traders, the current open interest surge in Zydus Lifesciences’ derivatives market signals a strategic opportunity to capitalise on the stock’s upward momentum. The combination of technical strength, rising investor participation, and positive mojo grading suggests that the stock is well-positioned for further gains in the near term.
However, investors should remain mindful of the inherent volatility in mid-cap pharmaceutical stocks, which can be influenced by regulatory developments, product approvals, and broader market conditions. Continuous monitoring of open interest trends and volume patterns will be crucial to gauge the sustainability of the current bullish sentiment.
Conclusion
Zydus Lifesciences Ltd’s recent surge in open interest and robust volume activity in the derivatives segment reflects a clear shift towards bullish market positioning. Supported by strong price performance, improved mojo ratings, and increased investor participation, the stock stands out as a compelling mid-cap opportunity within the Pharmaceuticals & Biotechnology sector. Market participants appear to be placing directional bets anticipating further upside, making Zydus Lifesciences a stock to watch closely in the coming weeks.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
